Moderna (MRNA) Stock May Be Fully Priced As Melanoma Vaccine Data Leaks

What happened: Moderna shares have drawn valuation scrutiny after a melanoma vaccine data leak and news on mRNA flu and bird flu programs, with analysis questioning whether the current price is supported by sales. Key numbers: Stock up roughly 7x over the past 12 months. P/S of 35.9x versus biotech industry 11.1x and peer group 6.7x. Market cap around US$70b. Why it matters: The model's fair multiple sits well below the current P/S, so shares screen as overvalued on that framework, though the wide gap is described as more a warning flag on losses and execution risk than a precise target. Market: -1.2% today ($200.10), +548.4% YTD, 1.1x vol — as of 23:45 UTC

Moderna shares have drawn valuation scrutiny after a melanoma vaccine data leak and news on mRNA flu and bird flu programs, with analysis questioning whether the current price is supported by sales.

The model's fair multiple sits well below the current P/S, so shares screen as overvalued on that framework, though the wide gap is described as more a warning flag on losses and execution risk than a precise target. Market: -1.2% today ($200.10), +548.4% YTD, 1.1x vol — as of 23:45 UTC